Fexuclue Gets Additional Indication for H. pylori Eradication
Additional indication approval for Fexuclue 40mg (fexuprazan hydrochloride) for H. pylori eradication (MFDS, 2026.04.30)
Korea's 34th new drug, already on the market
Estimated 50% global infection rate; expected to address resistance issues
Launch after marketing strategy formulation
KOSPI Filing Information
Filing: Major Management Matters Related To Investment Decision (Domestic Product Approval For Additional Indication Of Fexuclue Tablet (Fexuclue) (Antibiotic Combination Therapy For Helicobacter pylori Eradication))